Literature DB >> 25246753

Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis.

Ji Eun Lee1, Duck Hyun Ryu1, Ho Jung Jeong1, Jung Hoon Kim1, Ji Eun Jun1, June Soo Kim1, Soo Youn Lee2.   

Abstract

A 73-yr-old Korean man with permanent atrial fibrillation visited outpatient clinic with severely increased International Normalized Ratio (INR) values after taking a usual starting dosage of warfarin to prevent thromboembolism. We found out later from his blood tests that he had hyperthyroidism at the time of treatment initiation. His genetic analysis showed CYP2C9*1/*3 and VKORC1+1173TT genotypes. We suspect that both hyperthyroidism and genetic variant would have contributed to his extremely increased INR at the beginning of warfarin therapy. From this case, we learned that pharmacogenetic and thyroid function test might be useful when deciding the starting dosage of warfarin in patients with atrial fibrillation.

Entities:  

Keywords:  Genotype; International Normalized Ratio; Thyrotoxicosis; Warfarin

Mesh:

Substances:

Year:  2014        PMID: 25246753      PMCID: PMC4168188          DOI: 10.3346/jkms.2014.29.9.1317

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  11 in total

1.  Warfarin-induced hypoprothrombinemia. Potentiation by hyperthyroidism.

Authors:  T Self; M Weisburst; E Wooten; A Straughn; J Oliver
Journal:  JAMA       Date:  1975-03-17       Impact factor: 56.272

Review 2.  Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.

Authors:  Luca Tomisti; Marzia Del Re; Luigi Bartalena; Maria L Tanda; Angelo Pucci; Franco Pambianco; Romano Danesi; Lewis E Braverman; Enio Martino; Fausto Bogazzi
Journal:  Endocr Pract       Date:  2013 Nov-Dec       Impact factor: 3.443

Review 3.  Prediction of warfarin dose: why, when and how?

Authors:  Niclas Eriksson; Mia Wadelius
Journal:  Pharmacogenomics       Date:  2012-03       Impact factor: 2.533

4.  Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis.

Authors:  A G Vagenakis; R Cote; M E Miller; L E Braverman; F Stohlman
Journal:  Johns Hopkins Med J       Date:  1972-07

Review 5.  The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis.

Authors:  Danka J F Stuijver; Bregje van Zaane; Erica Romualdi; Dees P M Brandjes; Victor E A Gerdes; Alessandro Squizzato
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

6.  Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Authors:  Cong Ma; Yuxiao Zhang; Qiang Xu; Jie Yang; Yan Zhang; Lei Gao; Bin Xu; Hongjuan Wang; Yang Li; Caiyi Lu; Tong Yin
Journal:  Int J Hematol       Date:  2012-10-27       Impact factor: 2.490

7.  Problems of anticoagulation with warfarin in hyperthyroidism.

Authors:  H A Kellett; J S Sawers; F E Boulton; S Cholerton; B K Park; A D Toft
Journal:  Q J Med       Date:  1986-01

Review 8.  Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland.

Authors:  Daniel Kurnik; Ronen Loebstein; Zvi Farfel; David Ezra; Hillel Halkin; David Olchovsky
Journal:  Medicine (Baltimore)       Date:  2004-03       Impact factor: 1.889

9.  Apathetic thyrotoxicosis due to hemorrhage into a hyperfunctioning thyroid nodule after excessive anticoagulation.

Authors:  D Olchovsky; A Pines; S T Zwas; Y Itzchak; H Halkin
Journal:  South Med J       Date:  1985-05       Impact factor: 0.954

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.